Satish Shah, MD
Hematology & Oncology · Gettysburg, PANPI 1487679593
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $139,306 of the $180,097 with a category attached, or 77.4%. 60 manufacturers reported payments, led by Astrazeneca AB at 44.7% of the total. Reporting peaked in 2020 at $70,977 and has fallen 89.5% since, to $7,478 in 2025. Among hematology & oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $504.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca AB$81K
- Pharmacosmos Therapeutics Inc.$37K
- AstraZeneca$18K
- Astrazeneca UK Limited$7K
- Sanofi$6K
- Tesaro, Inc.$3K
- plus $28K from 54 others
Across 234 payments — averaging $5282.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- G1 Therapeutics, Inc.$372K
- Astrazeneca AB$269K
- Theratechnologies Inc.$118K
- AstraZeneca$109K
- Regeneron$74K
- Merck$68K
- plus $227K from 13 others
What the payments were for
- Consulting fees$139,30677%
- Speaking & faculty fees$19,08511%
- Travel & lodging$10,3886%
- Food & beverage$10,7336%
- Education$5850%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$180,097 in reported general payments places this provider in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 193 | $1,424,992 |
| JakafiRuxolitinib Phosphate | 42 | $840,472 |
| XtandiEnzalutamide | 38 | $504,252 |
| ProcritEpoetin Alfa | 148 | $410,638 |
| ImbruvicaIbrutinib | 22 | $379,023 |
| TecentriqAtezolizumab | 34 | $360,126 |
| CalquenceAcalabrutinib Maleate | 21 | $321,990 |
| Lupron DepotLeuprolide Acetate | 100 | $303,443 |
| XgevaDenosumab | 90 | $281,313 |
| OgivriTrastuzumab-Dkst | 72 | $280,665 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 41 | $249,183 |
| ReblozylLuspatercept-Aamt | 12 | $229,611 |
| KeytrudaPembrolizumab | 21 | $226,491 |
| TrodelvySacituzumab Govitecan-Hziy | 18 | $217,612 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 20 | $196,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Eliquis | $73 | $1,440,798223 claims |
| Incyte CorporationJakafi | $1,351 | $840,47242 claims |
| Astellas Pharma US IncXtandi | $83 | $504,25238 claims |
| AmgenXgeva, Mvasi, Prolia | $1,981 | $502,685146 claims |
| Johnson & JohnsonProcrit | $329 | $410,638148 claims |
| E.r. Squibb & Sons, L.L.C.Reblozyl, Opdivo | $1,817 | $350,38723 claims |
| AstraZenecaCalquence | $17,942 | $321,99021 claims |
| AbbVieLupron Depot | $57 | $303,443100 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $78 | $249,18341 claims |
| MerckKeytruda | $96 | $226,49121 claims |
| GileadTrodelvy | $63 | $217,61218 claims |
| Bristol Myers SquibbAbraxane | $877 | $149,19839 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Gettysburg
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Usama GergisAllentown$1.2M
- Kit LuHarrisburg$810K
- Henry FungPhiladelphia$730K
- Alexander BarsoukPittsburgh$674K
- Abdalla SholiWilliamsport$576K
- Charu AggarwalPhiladelphia$541K
- Tracey EvansEast Norriton$500K
- Corey LangerPhiladelphia$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.